Research Highlights: In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and reduced triglycerides by...
  • offspec@lemmy.worldEnglish
    2·
    6 days ago

    I feel obligated to mention that he doesn’t modify his own genes, he infects himself with a modified bacteria that produces lactase.